Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Locally Recurrent or Metastatic Breast Cancer

In brief

The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.

Key facts

Study ID

NCT01256762

Run by

Geron Corporation

People needed

166

Starts

2010-11-01

Expected to finish

2012-12-01

Last updated by the study team

2016-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed adenocarcinoma of the breast that is either locally recurrent or metastatic. Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent
• Either have not received chemotherapy or may have had one prior non-taxane chemotherapy regimen for metastatic disease (there are no restrictions on prior hormonal therapy)
• Prior use of bevacizumab is allowed provided that it was not administered in combination with a taxane
• ECOG performance status 0-1
• Adequate bone marrow reserve as indicated by:
• ANC > 1500/uL (without use of growth factors within 7 days)
• Platelet count > 100,000 (without transfusion in prior 7 days)
• Hemoglobin > 9.0 g/dL

You may not qualify if…

• Women who are pregnant or breast feeding
• Locally recurrent disease amenable to resection with curative intent
• HER-2-positive breast cancer
• Active central nervous system (CNS) metastatic disease including those patients receiving radiotherapy and/or steroid treatment (within the last 3 months)
• Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior of first relapse
• Investigational therapy within 4 weeks of first study drug administration
• Prior radiation, cytotoxic, or hormonal therapy within 2 weeks of first study drug administration
• Therapeutic anti-coagulation or regular use of anti-platelet therapy within 2 weeks prior to first study drug administration (low dose anti-coagulant therapy to maintain patency of a vascular access device is allowed)
• Grade ≥ 2 neuropathy
• Uncontrolled clinically significant atrial or ventricular arrhythmias (unless pacemaker in place)
• Severe conduction disturbance including clinically significant QTC prolongation > 450 ms (unless pacemaker in place)
• Active or chronically recurrent bleeding (e.g., active peptic ulcer disease)
• Clinically relevant active infection
• Known positive serology for human immunodeficiency virus (HIV)

Where it is running

• Alta Bates Summit Medical Center — Berkeley, California, United States
• Southbay Oncology Hematology Partners — Campbell, California, United States
• Cancer Care Associates — Fresno, California, United States
• Memorial Miller Hospital — Long Beach, California, United States
• St. Joseph Hospital — Orange, California, United States
• Desert Regional Comprehensive Cancer Center — Palm Springs, California, United States
• UC San Diego — San Diego, California, United States
• Redwood Regional Medical Group — Santa Rosa, California, United States
• Univ. Colorado at Denver — Aurora, Colorado, United States
• Connecticut Oncology & Hematology — Torrington, Connecticut, United States
• Medical Oncology Hematology — Waterbury, Connecticut, United States
• Florida Oncology Associates — Jacksonville, Florida, United States
• Hematology Oncology Associates — Port Saint Lucie, Florida, United States
• H. Lee Moffitt Cancer Center — Tampa, Florida, United States
• Northeast Georgia Cancer Care — Athens, Georgia, United States
• Peachtree Hematology Oncology — Atlanta, Georgia, United States
• Emory University — Atlanta, Georgia, United States
• Northeast Georgia Medical Center — Gainesville, Georgia, United States
• Central Georgia Cancer Care — Macon, Georgia, United States
• Summit Cancer Care — Savannah, Georgia, United States
• Kootenai Medical Center — Post Falls, Idaho, United States
• Ingalls Memorial Hospital — Chicago, Illinois, United States
• Rush University — Chicago, Illinois, United States
• Mid Illinois Hematology & Oncology — Normal, Illinois, United States
• Clearview Cancer Center — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.